Schonfeld Strategic Advisors’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Schonfeld Strategic Advisors’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,158	Closed	-$505K	–	2523
2024 Q3	$505K	Sell	15,158 -81,167	-84%	-$2.79M	﹤0.01%	1425
2024 Q2	$2.6M	Sell	96,325 -136,645	-59%	-$2.69M	0.02%	792
2024 Q1	$5.03M	Buy	232,970 +140,670	+152%	+$3.07M	0.03%	643
2023 Q4	$557K	Buy	92,300 +8,300	+10%	+$41.4K	﹤0.01%	1249
2023 Q3	$467K	Sell	84,000 -3,000	-3%	-$19.3K	﹤0.01%	1221
2023 Q2	$639K	Buy	+87,000	New	+$659K	0.01%	1126

Schonfeld Strategic Advisors's LBPH Position: Q4 2024 in Review

Schonfeld Strategic Advisors sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 15,158 shares — an estimated $505K sold.

Schonfeld Strategic Advisors first reported a position in LBPH in Q2 2023 and held it in 6 quarters. The position peaked at $5.03M in Q1 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

Schonfeld Strategic Advisors reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Schonfeld Strategic Advisors sold 15,158 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $505K.
Schonfeld Strategic Advisors first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 6 quarters.
Schonfeld Strategic Advisors's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $5.03M in Q1 2024.
0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.